bluebird bio (BLUE) Trading 0% Higher

bluebird bio Inc (NASDAQ:BLUE) shares traded up 0% during mid-day trading on Wednesday . The company traded as high as $174.30 and last traded at $173.10. 882,694 shares were traded during trading, an increase of 0% from the average session volume of 878,445 shares. The stock had previously closed at $173.10.

A number of research analysts have issued reports on the company. BidaskClub lowered bluebird bio from a “hold” rating to a “sell” rating in a research report on Wednesday. ValuEngine upgraded bluebird bio from a “hold” rating to a “buy” rating in a report on Monday. Canaccord Genuity restated a “buy” rating on shares of bluebird bio in a report on Wednesday, March 28th. Morgan Stanley upped their price objective on bluebird bio from $152.00 to $209.00 and gave the company an “equal weight” rating in a report on Wednesday, March 21st. Finally, Zacks Investment Research upgraded bluebird bio from a “sell” rating to a “hold” rating in a report on Tuesday, March 20th. Four investment analysts have rated the stock with a sell rating, nine have issued a hold rating and thirteen have issued a buy rating to the stock. bluebird bio has an average rating of “Hold” and an average target price of $195.20.

How to Become a New Pot Stock Millionaire

The stock has a market capitalization of $8,652.15, a PE ratio of -22.07 and a beta of 2.16.

bluebird bio (NASDAQ:BLUE) last announced its earnings results on Wednesday, February 21st. The biotechnology company reported ($2.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.68) by ($0.84). The company had revenue of $4.17 million for the quarter, compared to analyst estimates of $7.11 million. bluebird bio had a negative return on equity of 28.09% and a negative net margin of 947.42%. The firm’s revenue for the quarter was up 169.0% on a year-over-year basis. During the same period last year, the firm earned ($1.88) earnings per share. sell-side analysts expect that bluebird bio Inc will post -8.39 EPS for the current fiscal year.

In related news, COO Susanna Gatti High sold 17,262 shares of the company’s stock in a transaction on Tuesday, January 30th. The stock was sold at an average price of $195.91, for a total transaction of $3,381,798.42. Following the transaction, the chief operating officer now directly owns 28,512 shares of the company’s stock, valued at $5,585,785.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider David Davidson sold 3,522 shares of the company’s stock in a transaction on Monday, January 8th. The shares were sold at an average price of $173.61, for a total value of $611,454.42. Following the transaction, the insider now directly owns 13,959 shares in the company, valued at $2,423,421.99. The disclosure for this sale can be found here. Insiders have sold 80,034 shares of company stock worth $15,122,163 over the last ninety days. 3.90% of the stock is owned by insiders.

A number of large investors have recently bought and sold shares of BLUE. Meeder Asset Management Inc. raised its position in bluebird bio by 2,110.3% during the fourth quarter. Meeder Asset Management Inc. now owns 641 shares of the biotechnology company’s stock valued at $114,000 after buying an additional 612 shares during the period. NuWave Investment Management LLC acquired a new position in bluebird bio during the fourth quarter valued at $135,000. Ladenburg Thalmann Financial Services Inc. raised its position in bluebird bio by 454.2% during the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 992 shares of the biotechnology company’s stock valued at $136,000 after buying an additional 813 shares during the period. D.A. Davidson & CO. acquired a new position in bluebird bio during the fourth quarter valued at $214,000. Finally, Quinn Opportunity Partners LLC acquired a new position in bluebird bio during the fourth quarter valued at $232,000.

TRADEMARK VIOLATION NOTICE: This story was first reported by Ticker Report and is the property of of Ticker Report. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. & international trademark and copyright laws. The original version of this story can be viewed at https://www.tickerreport.com/banking-finance/3335212/bluebird-bio-blue-trading-0-higher.html.

bluebird bio Company Profile

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Grimcoin Trading Up 33.5% This Week
Grimcoin Trading Up 33.5% This Week
Lazaruscoin  Price Tops $0.0009 on Major Exchanges
Lazaruscoin Price Tops $0.0009 on Major Exchanges
8X8  Coverage Initiated by Analysts at CIBC
8X8 Coverage Initiated by Analysts at CIBC
Conatus Pharmaceuticals  Reaches New 1-Year High and Low at $3.46
Conatus Pharmaceuticals Reaches New 1-Year High and Low at $3.46
Lifetime Brands  Sets New 1-Year High and Low at $11.23
Lifetime Brands Sets New 1-Year High and Low at $11.23
Independent Bank  Announces  Earnings Results, Misses Expectations By $0.04 EPS
Independent Bank Announces Earnings Results, Misses Expectations By $0.04 EPS


Leave a Reply

© 2006-2018 Ticker Report. Google+.